Inotiv, Inc.

Overview

• IndustryServices-Commercial Physical & Biological Research¹
• HeadquartersWest Lafayette, Indiana¹
• Incorporated inIN²
• Business address2701 Kent Ave, West Lafayette, In 47906-1382²
• Filer categoryAccelerated filer²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Inotiv, Inc. and its subsidiaries (“we,” “our,” “us,” the “Company,” or “Inotiv”) began operating in 1975 as Bioanalytical Systems, Inc. Bioanalytical Systems, Inc. was incorporated in 1974 and completed an initial public offering in 2000. On March 18, 2021, the Company changed its corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. Our stock is traded on The Nasdaq Stock Market LLC under the symbol “NOTV.” We are headquartered in West Lafayette, Indiana. Our headquarters mailing address is 2701 Kent Avenue, West Lafayette, Indiana 47906, and the telephone number at that location is (765) 463-4527. Our Internet site is www.inotiv.com. The information contained on our website is not a part of this Report and is not incorporated by reference herein.⁴ From its latest annual report

Corporate structure

Inotiv, Inc. sits at the top of its group. 27 entities, 7 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Inotiv, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

As of September 30, 2025, we operate across 22 sites, encompassing 34 owned or leased facilities, predominantly comprised of vivariums and labs spread across four countries, and one manufacturing site in the U.S. Additionally, we have 14 distribution hubs/warehouse facilities across four countries and one administrative office in the U.S. Our facilities are in the U.K. and Europe (approximately 14% of facilities) and in the U.S. (approximately 86% of facilities). Our corporate headquarters is in West Lafayette, Indiana.

We believe that our facilities are adequate for our current operations and that suitable additional space will be available if and when needed, including to the extent necessary to expand operations.

Item 2 of the 10-K filed Dec 5, 2025.⁴

Leadership

Who has led Inotiv, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRobert Leasure Jr. Jan 16, 2019 to now¹⁴
• Chief executive officerJacqueline M. Lemke Aug 20, 2012 to Mar 2, 2016¹⁵
• Chief executive officerAnthony S. Chilton May 14, 2010 to Apr 11, 2012¹⁶
• Chief executive officerRichard M. Shepperd Oct 5, 2006 to Mar 20, 2008¹⁷
• PresidentRobert Leasure Jr. Jan 16, 2019 to now¹⁴
• PresidentJacqueline M. Lemke Mar 3, 2015 to Mar 2, 2016¹⁸
• PresidentAnthony S. Chilton May 14, 2010 to Apr 11, 2012¹⁶
• PresidentRichard M. Shepperd Oct 5, 2006 to Mar 20, 2008¹⁷
• Chief financial officerJill Blumhoff May 16, 2016 to Dec 4, 2019¹⁹
• Chief financial officerJeffrey Potrzebowski Jun 10, 2014 to Jun 10, 2014²⁰
• Chief financial officerJacqueline M. Lemke Apr 5, 2012 to Jan 17, 2013²¹
• Chief operating officerJohn Gregory Beattie Feb 16, 2021 to now²²
• Chief operating officerDaniel Thomas Oakley Feb 12, 2019 to Dec 4, 2019²³
• Chief operating officerAnthony S. Chilton Dec 9, 2008 to Feb 3, 2010²⁴
• Chief operating officerRonald E. Shoup Jun 2, 2006 to Jun 15, 2006²⁵

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerBeth A. Taylor named Oct 19, 2021 to Nov 16, 2021⁶⁷
• Executive OfficerGreg A. Beattie named Nov 16, 2021⁶⁷
• Executive OfficerJames A. Harkness named Nov 16, 2021⁶⁷
• Executive OfficerMichael A. Garrett named Nov 16, 2021⁶⁷
• DirectorGregory C. Davis named Nov 16, 2021⁶⁷
• DirectorNigel C. Brown named Nov 16, 2021⁶⁷
• DirectorR Matthew Neff named Oct 19, 2021 to Nov 16, 2021⁶⁷
• DirectorRichard A. Johnson named Nov 16, 2021⁶⁷
• DirectorGregory Matthew Davis named Oct 19, 2021⁶⁸
• DirectorRichard Matthew Johnson named Oct 19, 2021⁶⁸

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• 1 Inotiv Research Models, LLC Indiana³
• 10 Inotiv Nashville, LLC Indiana³
• 11 Envigo Global Services, Inc. Pennsylvania³
• 12 ERPP, Inc. Delaware³
• 13 Inotiv LAMS West, Inc. Texas³
• 14 Envigo RMS, LLC Delaware³
• 15 Precisium Solutions, LLC Delaware³
• 16 Envigo RMS GmbH Germany³
• 17 Envigo RMS S.L. Spain³
• 18 Envigo RMS S.A.R.L. France³
• 19 Envigo RMS, S.r.l. Italy³
• 2 BAS Evansville, Inc. Indiana³
• 20 Envigo Holdings Ltd. United Kingdom³
• 21 Envigo RMS BV Netherlands³
• 22 Envigo RMS B.V., Inc. Delaware³
• 23 Envigo Holding I, Inc. Delaware³
• 24 Envigo Bioproducts, Inc. Indiana³
• 25 Envigo New Holdco, LLC Delaware³
• 26 Envigo RMS (UK) Ltd. United Kingdom³
• 3 Seventh Wave Laboratories, LLC Indiana³
• 4 BASi Gaithersburg, LLC Indiana³
• 5 Inotiv Nashville, LLC Indiana³
• 6 Inotiv Boulder, LLC Indiana³
• 7 Integrated Laboratory Systems, LLC North Carolina³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• BIOANALYTICAL SYSTEMS INCNov 25, 1997 to Mar 9, 2021²

Timeline

1. Jul 16, 20268-K Bankruptcy or receivership; Regulation FD disclosure⁶⁹
2. Jun 8, 20268-K Other events⁷⁰
3. Jun 3, 20268-K Entered a material agreement; Bankruptcy or receivership; Debt or obligation accelerated⁷¹
4. Jun 1, 20268-K Entered a material agreement; New debt or obligation⁷²
5. May 18, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation⁷³
6. May 5, 20268-K Other events⁷⁴
7. Apr 21, 20268-K Other events⁷⁵
8. Apr 7, 20268-K Other events⁷⁶
9. Mar 24, 20268-K Other events⁷⁷
10. Mar 10, 20268-K Other events⁷⁸
11. Feb 9, 20268-K Results of operations⁷⁹
12. Jan 16, 20268-K Other events⁸⁰
13. Jan 16, 2019New chief executive Robert Leasure Jr. becomes CEO¹⁴
14. Aug 20, 2012New chief executive Jacqueline M. Lemke becomes CEO¹⁵
15. May 14, 2010New chief executive Anthony S. Chilton becomes CEO¹⁶
16. Oct 5, 2006New chief executive Richard M. Shepperd becomes CEO¹⁷

Calendar

When it reported results

1. Feb 9, 2026Reported quarterly or annual results⁷⁹
2. Dec 3, 2025Reported quarterly or annual results⁸¹
3. Nov 17, 2025Reported quarterly or annual results⁸²
4. Aug 7, 2025Reported quarterly or annual results⁸³
5. Aug 6, 2025Reported quarterly or annual results⁸⁴
6. May 7, 2025Reported quarterly or annual results⁸⁵
7. Feb 5, 2025Reported quarterly or annual results⁸⁶
8. Dec 3, 2024Reported quarterly or annual results⁸⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

352 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 69 major events, 180 insider forms, 11 large holders, 2 private raises, 67 other. The latest 20:

1. Jul 29, 202615-12G EDGAR
2. Jul 29, 20268-K15D5 EDGAR
3. Jul 27, 2026EFFECT EDGAR
4. Jul 27, 2026EFFECT EDGAR
5. Jul 27, 2026EFFECT EDGAR
6. Jul 20, 20264 EDGAR
7. Jul 20, 20264 EDGAR
8. Jul 20, 20264 EDGAR
9. Jul 20, 20264 EDGAR
10. Jul 20, 20264 EDGAR
11. Jul 20, 20264 EDGAR
12. Jul 20, 20264 EDGAR
13. Jul 20, 20264 EDGAR
14. Jul 20, 20264 EDGAR
15. Jul 20, 20264 EDGAR
16. Jul 20, 20264 EDGAR
17. Jul 20, 20264 EDGAR
18. Jul 20, 2026S-8 POS EDGAR
19. Jul 20, 2026S-8 POS EDGAR
20. Jul 20, 2026S-8 POS EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 23 buys and 27 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Jermyn Street Associates LLCSC 13D/A, 4 filings Nov 15, 2021 to Apr 3, 2024⁸⁸
• ISZO CAPITAL LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁸⁹
• P2 Capital Partners, LLCSC 13D/A, 2 filings Nov 15, 2021 to Sep 20, 2022⁹⁰
• Portolan Capital Management, LLCSC 13G/A, 2 filings Oct 21, 2021 to Feb 11, 2022⁹¹
• RENAISSANCE TECHNOLOGIES LLCSC 13G/A, 1 filing Feb 10, 2022⁹²

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Nov 5, 2021Raised $275 million in a private offering of equity Form D: 71 investors so far Form D
2. Oct 4, 2021Raised $5 million in a private offering of securities Form D: 39 investors so far Form D

SEC filer profile

How Inotiv, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARInotiv, Inc.¹
• CIK0000720154
• Employer ID (EIN)35-1345024⁴
• Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inIndiana⁴
• Fiscal year endsSeptember 30¹
• Industry code (SIC)8731 Services-Commercial Physical & Biological Research¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address2701 Kent Ave, West Lafayette, IN 47906-1382¹
• Mailing address2701 Kent Avenue, West Lafayette, IN 47906-1382¹
• Phone3174634527¹
• Shares outstanding34,888,147 as of Apr 16, 2026¹¹
• Public float$71.3M as of Mar 31, 2025⁴
• AuditorErnst & Young LLP, Indianapolis, IN PCAOB ID 42; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceSep 26, 1997¹
• Filings1,141 in all: 4 (352), 8-K (286), 10-Q (86), 3 (61), 10-K (28), DEF 14A (28), 8-K/A (21), CORRESP (19)¹
  All 54 form types

  S-8 POS (19), UPLOAD (18), S-8 (15), 10-Q/A (13), SC 13G (13), SC 13G/A (13), 10-K/A (12), 424B3 (12), SC 13D/A (11), DEFA14A (10), EFFECT (10), NT 10-Q (9), SC 13D (9), 3/A (8), NT 10-K (8), 144 (7), 4/A (7), 424B5 (6), POS AM (6), S-1/A (6), CT ORDER (4), S-3 (4), S-4/A (4), 425 (3), ARS (3), D (3), DEFR14A (3), S-1 (3), 424B7 (2), FWP (2), POS EX (2), 15-12G (1), 25-NSE (1), 424B1 (1), 424B4 (1), 8-A12G (1), 8-K15D5 (1), DEFM14A (1), DFAN14A (1), PRE 14A (1), PREM14A (1), RW (1), S-1MEF (1), S-3/A (1), S-4 (1), S-4 POS (1)

• Latest filingsAnnual report (10-K) Dec 5, 2025
  Quarterly report (10-Q) May 11, 2026
  Proxy statement (DEF 14A) Jan 23, 2025
  Latest 8-K (8-K) Jul 16, 2026

Securities registered for trading

From the cover page of the 10-K filed Dec 5, 2025 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Inotiv, Inc. names in Item 1A of its 10-K filed Dec 5, 2025: 42 risks under these headings, as written.⁴

• All dollar amounts shown within this Part I, Item 1A are presented in thousands.
• Risks Related to our Financial Activities
• We have identified conditions and events that could raise substantial doubt about our ability to continue as a going concern.
• We have experienced periods of losses and financial insecurity.
• We have significant indebtedness, which may impair our ability to raise capital or impact our ability to service our debt.
• Our Credit Agreement contains covenants that restrict our business and financing activities. Our assets secure our obligations under the Credit Agreement and the Second Lien Notes and may be subject to foreclosure.
• Our failure to comply with the terms of our Credit Agreement could result in an event of default that could materially adversely affect our business, financial condition and results of operations.
• We may need additional capital, and any additional capital we seek may not be available in the amount or at the time we need it.
• Risks Related to NHP Supply and Demand
• Our business, results of operations, financial condition, including the carrying value of certain of our assets, and cash flows have been, and may continue to be, adversely affected by our dependence on the importation of non-human primates ("NHPs") from suppliers located outside the U.S., particularly from certain countries in Southeast Asia and Africa, legal issues related to these suppliers, increased costs associated with trade and economic factors, including tariffs, and any inability to diversify our suppliers located outside the U.S.
• Our sales of NHPs have decreased significantly in recent periods, which adversely affected our business, financial condition and results of operations, and this trend may continue.
• Risks Related to Technology and Cybersecurity

Legal proceedings

Information pertaining to legal proceedings can be found in Note 15 - Contingencies and Commitments to the Consolidated Financial Statements included in Part II, Item 8 of this Report and is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.⁴